Assessment of knowledge, attitudes, and practices of CML patients and their families toward TKI therapy in China.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
15 Dec 2023
15 Dec 2023
Historique:
medline:
20
12
2023
pubmed:
20
12
2023
entrez:
20
12
2023
Statut:
ppublish
Résumé
The introduction of tyrosine kinase inhibitors (TKIs) has revolutionized chronic myeloid leukemia (CML) treatment. The knowledge, attitude, and practice (KAP) of patients and their families play a significant role in treatment adherence and effectiveness. This study aimed to investigate the KAP of CML patients and their families regarding TKI therapy in China. From November 1 to December 31, 2022, a cross-sectional study was conducted at the Affiliated Huai'an No. 1 People's Hospital in China. A total of 313 CML patients and 268 family caregivers were selected using convenience sampling. Participants answered a self-designed questionnaire. The questionnaire contained demographic/clinical data and assessed KAP toward CML and TKI therapy. Participants exhibited mean KAP scores of 8.91 (55.7%), 33.10 (73.6%), and 2.20 (73.3%), respectively. Family members had higher knowledge and practice scores than patients (both P < .05), with factors such as younger age, urban residency, higher education, employment, higher income, and interaction with peers correlating with better knowledge scores (P < .001). Although participants were well-informed about their diagnosis and medication (>80%), understanding of disease causes (<30%) and treatment prognosis and side effects (<50%) was limited, and cost concerns affected 80.55%. Anxiety and depression were reported more among caregivers (46.64% and 13.8%) than patients (29.71% and 11.51%). While 84.85% adhered to the doctor's instructions, only 68.50% actively sought more CML information. Positive correlations were observed among KAP scores, indicating their interdependence (knowledge-attitude: R = 0.397; knowledge-practice: R = 0.598; attitude-practice: R = 0.353; all P < .001). The findings underscore the importance of tailored education to fill knowledge gaps about CML and the need to address financial concerns and provide psychological support. The positive correlations among knowledge, attitudes, and practices emphasize the need for comprehensive interventions. In conclusion, this study highlights the importance of tailored education, addresses financial concerns, and provides emotional support for CML patients and caregivers in China, despite limitations such as convenience sampling and questionnaire design. Future research should evaluate the effectiveness of educational interventions and long-term outcomes to further enhance the overall well-being of this population.
Identifiants
pubmed: 38115374
doi: 10.1097/MD.0000000000036498
pii: 00005792-202312150-00135
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e36498Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95:691–709.
Emole J, Talabi T, Pinilla-Ibarz J. Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib. Biologics. 2016;10:23–31.
Miranda-Filho A, Pineros M, Ferlay J, et al. Epidemiological patterns of leukaemia in 184 countries: a population-based study. Lancet Haematol. 2018;5:e14–24.
Hoglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94(Suppl 2):S241–7.
Chang CS, Lee K, Yang YH, et al. Estimation of CML incidence: disagreement between national cancer registry and health claims data system in Taiwan. Leuk Res. 2011;35:e53–54.
Chen Y, Wang H, Kantarjian H, et al. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma. 2013;54:1411–7.
Au WY, Caguioa PB, Chuah C, et al. Chronic myeloid leukemia in Asia. Int J Hematol. 2009;89:14–23.
Dyagil IS, Dmytrenko IV, Sholoiko VV, et al. Chronic myeloid leukemia course in persons exposed to ionizing radiation as a result of the chornobyl accident. Probl Radiac Med Radiobiol. 2020;25:443–55.
Jin MW, Xu SM, An Q, et al. A review of risk factors for childhood leukemia. Eur Rev Med Pharmacol Sci. 2016;20:3760–4.
Vlaanderen J, Lan Q, Kromhout H, et al. Occupational benzene exposure and the risk of chronic myeloid leukemia: a meta-analysis of cohort studies incorporating study quality dimensions. Am J Ind Med. 2012;55:779–85.
Hu Y, Li Q, Hou M, et al. Magnitude and temporal trend of the chronic myeloid leukemia: on the basis of the global burden of disease study 2019. JCO Glob Oncol. 2021;7:1429–41.
Guru Murthy GS, Atallah E. Treatment-free remission in CML: the US perspective. Curr Hematol Malig Rep. 2019;14:56–61.
Haque R, Shi J, Chung J, et al. Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO. J Am Pharm Assoc (2003). 2017;57:303–310.e2.
Noens L, Hensen M, Kucmin-Bemelmans I, et al. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica. 2014;99:437–47.
Tan BK, Bee PC, Chua SS, et al. Monitoring and improving adherence to tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a systematic review. Patient Prefer Adherence. 2021;15:2563–75.
Kim Y, Go TH, Jang J, et al. Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia. Korean J Intern Med. 2021;36:1450–8.
Lam MS, Cheung N. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia. J Oncol Pharm Pract. 2016;22:741–8.
Kekale M, Talvensaari K, Koskenvesa P, et al. Chronic myeloid leukemia patients’ adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians. Patient Prefer Adherence. 2014;8:1619–27.
Wu S, Chee D, Ugalde A, et al. Lack of congruence between patients’ and health professionals’ perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: a qualitative study. Palliat Support Care. 2015;13:255–63.
Tan BK, Tan SB, Chen LC, et al. Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study. Patient Prefer Adherence. 2017;11:1027–34.
Gupta N, Mahapatra M, Seth T, et al. Social and financial barriers to optimum TKI treatment in patients with chronic myeloid leukemia-a knowledge-attitudes-practices study from India. Mediterr J Hematol Infect Dis. 2021;13:e2021004.
Langenberg S, Reyners AKL, Wymenga ANM, et al. Caregivers of patients receiving long-term treatment with a tyrosine kinase inhibitor (TKI) for gastrointestinal stromal tumour (GIST): a cross-sectional assessment of their distress and burden. Acta Oncol. 2019;58:191–9.
Andrade C, Menon V, Ameen S, et al. Designing and conducting knowledge, attitude, and practice surveys in psychiatry: practical guidance. Indian J Psychol Med. 2020;42:478–81.
Deininger MW, Shah NP, Altman JK, et al. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:1385–415.
Chen LC, Chen TC, Huang YB, et al. Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients. Int J Clin Pharm. 2014;36:120–7.
Ahlgren M, Funk T, Marimo C, et al. Management of noma: practice competence and knowledge among healthcare workers in a rural district of Zambia. Global Health Action. 2017;10:1340253.
Guo C, Hu B, Guo C, et al. A survey of pharmacogenomics testing among physicians, pharmacists, and researchers from China. Front Pharmacol. 2021;12:682020.
Efficace F, Breccia M, Cottone F, et al. Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. Support Care Cancer. 2016;24:4887–94.
Ali EE, Chan SSL, Leow JL, et al. User acceptance of an app-based adherence intervention: perspectives from patients taking oral anticancer medications. J Oncol Pharm Pract. 2019;25:390–7.
Jiang Q, Yu L, Gale RP. Patients’ and hematologists’ concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia. J Cancer Res Clin Oncol. 2018;144:735–41.
Eden RE, Coviello JM. Chronic Myelogenous Leukemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
Maaoui F, Moumni I, Arboix-Calas F, et al. Emotional and behavioral attitudes of Tunisian youth towards childhood leukemia: health education and primary prevention in perspective. BMC Public Health. 2022;22:2105.
Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6:211–24.
Phillips KM, Pinilla-Ibarz J, Sotomayor E, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013;21:1097–103.
Shi D, Li Z, Li Y, et al. Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Leuk Lymphoma. 2021;62:640–8.
Gibek K, Sacha T. Assessment of factors affecting the mental condition of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Psychiatr Pol. 2022;20:1–15.
Hao T, Li-Talley M, Buck A, et al. An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. Sci Rep. 2019;9:12070.
Daskalakis M, Feller A, Noetzli J, et al. The Nicer Working Group. Potential to improve therapy of chronic myeloid leukemia (CML), especially for patients with older age: incidence, mortality, and survival rates of patients with CML in Switzerland from 1995 to 2017. Cancers (Basel). 2021;13:6269.